DK3572416T3 - Diaryl macrocycles as modulators of protein kinases - Google Patents

Diaryl macrocycles as modulators of protein kinases Download PDF

Info

Publication number: DK3572416T3
Authority: DK; Denmark
Prior art keywords: modulators; protein kinases; macrocycles; diaryl; diaryl macrocycles
Prior art date: 2014-01-24

Application number

DK19169041.1T

Other languages

Danish (da)

Inventor

Jingrong Jean Cui

Yishan Li

Evan W Rogers

Dayong Zhai

Original Assignee

Turning Point Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-24

Filing date

2015-01-23

Publication date

2022-12-12

2015-01-23 Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc

2022-12-12 Application granted granted Critical

2022-12-12 Publication of DK3572416T3 publication Critical patent/DK3572416T3/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)

DK19169041.1T 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases DK3572416T3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201461931506P	2014-01-24	2014-01-24
US201462049326P	2014-09-11	2014-09-11
US201562106301P	2015-01-22	2015-01-22
EP15740510.1A EP3097107B1 (en)	2014-01-24	2015-01-23	Diaryl macrocycles as modulators of protein kinases

Publications (1)

Publication Number	Publication Date
DK3572416T3 true DK3572416T3 (en)	2022-12-12

Family

ID=53682127

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK19169041.1T DK3572416T3 (en)	2014-01-24	2015-01-23	Diaryl macrocycles as modulators of protein kinases
DK15740510.1T DK3097107T3 (en)	2014-01-24	2015-01-23	DIARYL MACROCYCLES AS PROTEIN KINASAS MODULATORS
DK19212110.1T DK3636649T3 (en)	2014-01-24	2015-01-23	DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK15740510.1T DK3097107T3 (en)	2014-01-24	2015-01-23	DIARYL MACROCYCLES AS PROTEIN KINASAS MODULATORS
DK19212110.1T DK3636649T3 (en)	2014-01-24	2015-01-23	DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

Country Status (35)

Country	Link
US (7)	US9714258B2 (en)
EP (6)	EP3636649B1 (en)
JP (5)	JP6490713B2 (en)
KR (1)	KR102402179B1 (en)
CN (3)	CN106170289B (en)
AP (1)	AP2016009383A0 (en)
AU (2)	AU2015209239B2 (en)
CA (1)	CA2936079C (en)
CL (1)	CL2016001876A1 (en)
CY (1)	CY1121850T1 (en)
DK (3)	DK3572416T3 (en)
EA (2)	EA201892241A1 (en)
ES (3)	ES2933350T3 (en)
FI (2)	FI3636649T3 (en)
FR (1)	FR25C1013I1 (en)
HR (3)	HRP20221518T1 (en)
HU (4)	HUE066590T2 (en)
IL (2)	IL246860B (en)
LT (4)	LT3572416T (en)
MX (2)	MX392904B (en)
MY (1)	MY193524A (en)
NL (1)	NL301322I2 (en)
NO (1)	NO2025015I1 (en)
NZ (2)	NZ761094A (en)
PE (1)	PE20160931A1 (en)
PH (1)	PH12016501463B1 (en)
PL (3)	PL3636649T3 (en)
PT (3)	PT3636649T (en)
RS (3)	RS59059B1 (en)
SG (2)	SG10202000191YA (en)
SI (3)	SI3572416T1 (en)
SM (3)	SMT202400175T1 (en)
UA (1)	UA121206C2 (en)
WO (1)	WO2015112806A2 (en)
ZA (2)	ZA201604654B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2350075B1 (en)	2008-09-22	2014-03-05	Array Biopharma, Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101853026B1 (en)	2008-10-22	2018-04-27	어레이 바이오파마 인크.	SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
AR077468A1 (en)	2009-07-09	2011-08-31	Array Biopharma Inc	PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
CN105693720B (en)	2010-05-20	2019-01-18	阵列生物制药公司	Macrocyclic compound as TRK kinase inhibitor
WO2015112806A2 (en)	2014-01-24	2015-07-30	Tp Therapeutics, Inc.	Diaryl macrocycles as modulators of protein kinases
TWI746426B (en)	2014-11-16	2021-11-21	美商亞雷生物製藥股份有限公司	Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10758525B2 (en)	2015-01-22	2020-09-01	MyoKardia, Inc.	4-methylsulfonyl-substituted piperidine urea compounds
KR20180021745A (en)	2015-06-01	2018-03-05	록쏘 온콜로지, 인코포레이티드	How to diagnose and treat cancer
ES2864839T3 (en) *	2015-07-02	2021-10-14	Turning Point Therapeutics Inc	Chiral diaryl macrocycles as modulators of protein kinases
ES2979111T3 (en) *	2015-07-06	2024-09-24	Turning Point Therapeutics Inc	Diaryl macrocycle polymorph
EP3322706B1 (en)	2015-07-16	2020-11-11	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX383823B (en) *	2015-07-21	2025-03-14	Turning Point Therapeutics Inc	CHIRAL DIARYL MACROCYCLES AND THEIR USES.
TN2018000138A1 (en)	2015-10-26	2019-10-04	Array Biopharma Inc	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US11278521B2 (en)	2015-12-15	2022-03-22	University Of South Florida	GAS5 binding compounds, formulations, and uses thereof
RS65988B1 (en)	2016-04-04	2024-10-31	Loxo Oncology Inc	Methods of treating pediatric cancers
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
HUE068971T2 (en)	2016-04-04	2025-02-28	Loxo Oncology Inc	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
SI3458456T1 (en)	2016-05-18	2021-04-30	Loxo Oncology, Inc.	Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN109715165A (en) *	2016-07-28	2019-05-03	Tp生物医药公司	Huge ring kinase inhibitor
TWI704148B (en)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en)	2016-10-10	2019-04-09	Array Biopharma Inc	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en)	2016-10-26	2019-04-25	Array Biopharma Inc	PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
CN110267960B (en)	2017-01-18	2022-04-26	阿雷生物药品公司	Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors
TWI808958B (en) *	2017-01-25	2023-07-21	美商特普醫葯公司	Combination therapy involving diaryl macrocyclic compounds
JOP20190213A1 (en)	2017-03-16	2019-09-16	Array Biopharma Inc	Macrocyclic compounds as ros1 kinase inhibitors
CN107586796B (en) *	2017-07-20	2021-08-06	暨明医药科技（苏州）有限公司	Synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol
MY201925A (en) *	2017-07-28	2024-03-23	Turning Point Therapeutics Inc	Macrocyclic compounds and uses thereof
TWI812649B (en)	2017-10-10	2023-08-21	美商絡速藥業公司	Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
EP3700576A1 (en)	2017-10-26	2020-09-02	Array Biopharma Inc.	Formulations of a macrocyclic trk kinase inhibitor
CN109516999B (en) *	2017-11-01	2021-08-17	郑州泰基鸿诺医药股份有限公司	Compounds useful as protein kinase modulators and uses thereof
WO2019094143A1 (en) *	2017-11-10	2019-05-16	Angex Pharmaceutical, Inc.	Macrocyclic compounds as trk kinase inhibitors and uses thereof
EP3728270A4 (en)	2017-12-19	2021-06-23	Turning Point Therapeutics, Inc.	Macrocyclic kinase inhibitors and their use
JP7194188B2 (en) *	2017-12-19	2022-12-21	ターニング・ポイント・セラピューティクス・インコーポレイテッド	Macrocycles for treating disease
WO2019120194A1 (en) *	2017-12-22	2019-06-27	深圳市塔吉瑞生物医药有限公司	Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof
TW201938169A (en)	2018-01-18	2019-10-01	美商亞雷生物製藥股份有限公司	Substituted pyrazolo[3,4-d]pyrimidine compounds as RET kinase inhibitors
CN111971286B (en)	2018-01-18	2023-04-14	阿雷生物药品公司	Substituted pyrrolo[2,3-d]pyrimidine compounds as RET kinase inhibitors
WO2019143994A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN109575025B (en)	2018-01-23	2020-09-11	深圳市塔吉瑞生物医药有限公司	Substituted pyrazolo[1,5-a]pyrimidines of macrocycles
WO2019149131A1 (en) *	2018-01-30	2019-08-08	上海吉倍生物技术有限公司	Compound having macrocyclic molecular structure and use thereof
CN110156813B (en) *	2018-02-13	2023-07-25	北京诺诚健华医药科技有限公司	Heterocyclic compounds as TRK inhibitors
AU2019241260B2 (en) *	2018-03-28	2022-06-16	Fochon Biosciences, Ltd.	Macrocyclic compounds as TRK kinases inhibitors
CA3095366A1 (en)	2018-03-29	2019-10-03	Loxo Oncology, Inc.	Treatment of trk-associated cancers
JP7092405B2 (en) *	2018-04-16	2022-06-28	深▲チェン▼市塔吉瑞生物医薬有限公司	Di (hetero) aryl macrocycle to inhibit kinase activity
CN111902417B (en) *	2018-04-25	2023-07-28	北京普祺医药科技股份有限公司	Diaryl macrocyclic compound, pharmaceutical composition and application thereof
CN111918868B (en) *	2018-05-04	2022-12-30	正大天晴药业集团股份有限公司	Diaryl macrocycles as protein kinase modulators
CN110627812B (en)	2018-06-25	2022-10-11	北京诺诚健华医药科技有限公司	Heterocyclic compounds as TRK inhibitors
KR102653681B1 (en)	2018-07-31	2024-04-03	록쏘 온콜로지, 인코포레이티드	SPRAY-DRIED DISPERSIONS AND FORMULATIONS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUORO PROPAN-2-YL)-lH-PYRAZOLE-4-CARBOXAMIDE
ES2922314T3 (en)	2018-09-10	2022-09-13	Array Biopharma Inc	Fused Heterocyclic Compounds as RET Kinase Inhibitors
CN110950889B (en) *	2018-09-27	2022-04-05	北京赛林泰医药技术有限公司	Multi-target kinase inhibitor and preparation method and application thereof
CN112955453B (en) *	2018-09-29	2022-04-19	山东绿叶制药有限公司	Pyrazolopyrimidine derivatives as selective Trk inhibitors
KR102850357B1 (en)	2018-10-22	2025-08-27	알루미스 인크.	TYK2 inhibitors and uses thereof
AU2019375825B2 (en) *	2018-11-09	2022-09-15	Shandong Xuanzhu Pharma Co., Ltd.	Macrocyclic tyrosine kinase inhibitor and uses thereof
CN111171049B (en) *	2018-11-09	2021-06-04	山东轩竹医药科技有限公司	Tyrosine kinase inhibitors and uses thereof
EP3883573B1 (en) *	2018-11-19	2024-07-31	Dana-Farber Cancer Institute, Inc.	Macrocyclic inhibitors of dyrk1a
EP3898626A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020131674A1 (en)	2018-12-19	2020-06-25	Array Biopharma Inc.	7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN111592541B (en) *	2019-02-21	2021-09-10	山东轩竹医药科技有限公司	Macrocyclic kinase inhibitors and uses thereof
AU2020239026B2 (en) *	2019-03-11	2025-10-09	Alumis Inc.	TYK2 inhibitors and uses thereof
BR112021019070A2 (en) *	2019-03-26	2022-02-15	Ventyx Biosciences Inc	tyk2 pseudokinase ligands
WO2020233645A1 (en) *	2019-05-21	2020-11-26	浙江海正药业股份有限公司	Macrolide derivatives, preparation method and application thereof
WO2020257189A1 (en) *	2019-06-19	2020-12-24	Turning Point Therapeutics, Inc.	Macrocycles for treating disease
WO2020257165A1 (en) *	2019-06-19	2020-12-24	Turning Point Therapeutics, Inc.	Macrocycles for use in treating disease
PE20220135A1 (en) *	2019-06-19	2022-01-27	Turning Point Therapeutics Inc	POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR
US20220306653A1 (en) *	2019-06-21	2022-09-29	Janssen Pharmaceutica Nv	Macrocyclic inhibitors of mcl-1
CN112110938B (en) *	2019-06-21	2021-11-09	成都海博为药业有限公司	Compound as protein kinase inhibitor and preparation method and application thereof
WO2021011586A1 (en)	2019-07-16	2021-01-21	MyoKardia, Inc.	Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
WO2021027503A1 (en) *	2019-08-12	2021-02-18	罗欣药业(上海)有限公司	Tricyclic compound, preparation method therefor, and intermediate and use thereof
CN114423762B (en) *	2019-09-30	2024-03-29	浙江海正药业股份有限公司	Macrocyclic derivatives and their preparation methods and uses
TW202133855A (en) *	2019-11-27	2021-09-16	美商特普醫葯公司	Combination therapy involving diaryl macrocyclic compounds
CA3163095A1 (en)	2019-11-27	2021-06-03	Turning Point Therapeutics, Inc.	Combination therapy involving diaryl macrocyclic compounds
CN114929710B (en) *	2019-12-03	2024-03-29	特普医药公司	Macrocyclic ring for the treatment of disease
WO2021113492A1 (en)	2019-12-06	2021-06-10	Schrödinger, Inc.	Cyclic compounds and methods of using same
MX2022007171A (en)	2019-12-27	2022-08-22	Schroedinger Inc	CYCLIC COMPOUNDS AND METHODS OF USE OF THESE.
CN113045587A (en) *	2019-12-27	2021-06-29	成都倍特药业股份有限公司	Crystal form of macrocyclic compound and preparation method thereof
CN113135938B (en) *	2020-01-19	2022-06-14	山东轩竹医药科技有限公司	Substituted macrocyclic tyrosine kinase inhibitors and uses thereof
CN115397514A (en) *	2020-03-02	2022-11-25	特普医药公司	Therapeutic uses of macrocyclic compounds
CU20220065A7 (en)	2020-05-04	2023-06-13	Amgen Inc	HETEROCYCLIC COMPOUNDS AS AGONISTS OF THE ACTIVATION RECEPTOR EXPRESSED ON MYELOID CELLS 2
JP7495035B2 (en) *	2020-05-08	2024-06-04	シュエンジュウバイオファーマシューティカルカンパニーリミテッド	Crystalline forms of macrocyclic tyrosine kinase inhibitors and methods for their preparation
US20230219978A1 (en) *	2020-06-04	2023-07-13	Scinnohub Pharmaceutical Co., Ltd	Compound having macrocyclic structure and use thereof
US20230257396A1 (en) *	2020-07-10	2023-08-17	Blossomhill Therapeutics, Inc.	Macrocycles and their use
EP4211140A1 (en)	2020-09-10	2023-07-19	Schrödinger, Inc.	Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
EP4284804A1 (en)	2021-01-26	2023-12-06	Schrödinger, Inc.	Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
WO2022182845A1 (en) *	2021-02-25	2022-09-01	Blossomhill Therapeutics, Inc.	Macrocycles and their use
TW202300150A (en)	2021-03-18	2023-01-01	美商薛定諤公司	Cyclic compounds and methods of using same
CN113754657B (en) *	2021-09-22	2023-01-17	广州白云山医药集团股份有限公司白云山制药总厂	Crystal form of macrocyclic compound, preparation method and application thereof
CN116063326B (en) *	2021-11-02	2025-08-05	赛诺哈勃药业（成都）有限公司	Amino-containing macrocyclic compounds as protein kinase modulators
CN116514813A (en) *	2021-12-31	2023-08-01	轩竹生物科技股份有限公司	Preparation method of tyrosine kinase inhibitor and intermediate thereof
CA3246487A1 (en) *	2022-01-05	2023-07-13	Blossomhill Therapeutics, Inc.	Macrocyclic compounds and use as kinase inhibitors
CN115746023B (en) *	2022-10-27	2024-08-09	复旦大学	Heterocyclic macrocyclic compound containing indazole structure as protein kinase inhibitor and preparation method thereof
WO2025059027A1 (en)	2023-09-11	2025-03-20	Schrödinger, Inc.	Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
WO2025217347A2 (en)	2024-04-11	2025-10-16	Bristol-Myers Squibb Company	Process of preparing repotrectinib
WO2025235733A1 (en) *	2024-05-09	2025-11-13	Blossomhill Therapeutics, Inc.	Bis-bicycloheteroaryl macrocycles and their use

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4838925A (en)	1986-04-25	1989-06-13	E. I. Du Pont De Nemours And Company	Heterocyclic acyl sulfonamides
EP0281841B1 (en)	1987-03-07	1990-11-14	Bayer Ag	Process for preparation of 5-amino-4,6-dihalogenopyridines
WO1994021608A1 (en)	1993-03-25	1994-09-29	The Upjohn Company	Indoletetralins having dopaminergic activity
AU687909B2 (en)	1993-12-07	1998-03-05	Eli Lilly And Company	Protein kinase C inhibitors
FR2746309B1 (en)	1996-03-22	1998-04-17	Oreal	COMPOSITION FOR DYEING KERATIN FIBERS CONTAINING PYRAZOLOPYRIMIDINEOXO; THEIR USE FOR DYEING AS COUPLER, DYEING PROCESSES
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
FR2793791B1 (en)	1999-05-19	2002-01-25	Univ Paris 7 Denis Diderot	NOVEL INHIBITOR COMPOUNDS SPECIFIC TO A2 PHOSPHOLIPASES
AU2001283955B2 (en)	2000-07-31	2006-05-18	F. Hoffmann-La Roche Ag	Piperazine derivatives
ATE301661T1 (en)	2000-12-08	2005-08-15	Ortho Mcneil Pharm Inc	MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
WO2002076925A2 (en)	2001-03-23	2002-10-03	Eli Lilly And Company	Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
WO2004052315A2 (en)	2002-12-11	2004-06-24	Merck & Co., Inc.	Tyrosine kinase inhibitors
US7970766B1 (en)	2007-07-23	2011-06-28	Google Inc.	Entity type assignment
JP5749645B2 (en) *	2008-09-08	2015-07-15	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	Macrocyclic pyrimidines as protein kinase inhibitors
EP2350075B1 (en)	2008-09-22	2014-03-05	Array Biopharma, Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101853026B1 (en)	2008-10-22	2018-04-27	어레이 바이오파마 인크.	SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
EP2348860B1 (en)	2008-10-31	2015-05-27	Genentech, Inc.	Pyrazolopyrimidine jak inhibitor compounds and methods
WO2010063487A1 (en)	2008-12-05	2010-06-10	Merz Pharma Gmbh & Co. Kgaa	Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en)	2009-01-29	2010-08-05	Biomarin Iga, Ltd.	Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (en)	2009-07-09	2011-08-31	Array Biopharma Inc	PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
US20110029480A1 (en)	2009-08-03	2011-02-03	IntelliCubes, Inc.	Method of Compiling Multiple Data Sources into One Dataset
ES2446720T3 (en)	2009-10-13	2014-03-10	Elanco Animal Health Ireland Limited	Macrocyclic Integrase Inhibitors
US9150577B2 (en)	2009-12-07	2015-10-06	Boehringer Ingelheim International Gmbh	Heterocyclic compounds containing an indole core
US9073926B2 (en)	2009-12-07	2015-07-07	Boehringer Ingelheim International Gmbh	Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
SA111320200B1 (en)	2010-02-17	2014-02-16	ديبيوفارم اس ايه	Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
CN105693720B (en)	2010-05-20	2019-01-18	阵列生物制药公司	Macrocyclic compound as TRK kinase inhibitor
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
UY33597A (en)	2010-09-09	2012-04-30	Irm Llc	COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
WO2012075393A2 (en)	2010-12-02	2012-06-07	President And Fellows Of Harvard College	Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) *	2011-04-07	2012-10-10	Helmholtz-Zentrum für Infektionsforschung GmbH	Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en)	2011-06-30	2013-01-03	Centro Nacional De Investigaciones Oncológicas (Cnio)	Macrocyclic compounds and their use as cdk8 inhibitors
EP2744507A4 (en) *	2011-08-19	2015-01-28	Merck Sharp & Dohme	CRYSTALLINE FORMS OF HCV PROTEASE INHIBITOR
WO2013045702A2 (en)	2011-09-29	2013-04-04	L'oreal	Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
WO2013045701A2 (en)	2011-09-29	2013-04-04	L'oreal	Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
GB2495134B (en)	2011-09-30	2014-06-11	Tridonic Uk Ltd	Power supply apparatus
US9090630B2 (en) *	2011-09-30	2015-07-28	Oncodesign S.A.	Macrocyclic FLT3 kinase inhibitors
CN104394869A (en)	2011-10-20	2015-03-04	葛兰素史密斯克莱有限责任公司	Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
ES2621220T3 (en)	2012-03-06	2017-07-03	Pfizer Inc.	Macrocyclic derivatives for the treatment of proliferative diseases
MX381849B (en)	2012-03-09	2025-03-13	Lexicon Pharmaceuticals Inc	PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
EP2822559B1 (en)	2012-03-09	2018-05-02	Lexicon Pharmaceuticals, Inc.	Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
EP2645540A1 (en)	2012-03-28	2013-10-02	Siemens Aktiengesellschaft	Corona shielding material for an electric machine
GB201205669D0 (en)	2012-03-30	2012-05-16	Agency Science Tech & Res	Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JP2016506921A (en)	2013-01-30	2016-03-07	バイエルファーマアクチエンゲゼルシャフト	Amino-substituted isothiazole
EP2989082A1 (en)	2013-04-23	2016-03-02	LEK Pharmaceuticals d.d.	Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof
WO2015012328A1 (en)	2013-07-24	2015-01-29	武田薬品工業株式会社	Heterocyclic compound
WO2015073267A1 (en)	2013-11-15	2015-05-21	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
WO2015112806A2 (en) *	2014-01-24	2015-07-30	Tp Therapeutics, Inc.	Diaryl macrocycles as modulators of protein kinases
WO2016070241A1 (en)	2014-11-03	2016-05-12	Ctxt Pty Ltd	Triazine compounds, compositions and synthesis
PL3233863T3 (en)	2014-12-15	2024-11-12	Cmg Pharmaceutical Co., Ltd.	Fused ring heteroaryl compounds and their use as trk inhibitors
CN107531666A (en)	2015-02-20	2018-01-02	里格尔药品股份有限公司	The inhibitor of GDF 8
EP3267996B1 (en)	2015-03-12	2020-11-11	Merck Sharp & Dohme Corp.	Pyrazolopyrimidine inhibitors of irak4 activity
EP3268367B8 (en)	2015-03-12	2022-11-16	Merck Sharp & Dohme LLC	Carboxamide inhibitors of irak4 activity
US20180148418A1 (en)	2015-05-05	2018-05-31	Bayer Pharma Aktiengesellschaft	Amido-substituted cyclohexane derivatives
US10894131B2 (en)	2015-06-29	2021-01-19	Q-Core Medical Ltd.	Methods circuits devices assemblies systems and associated computer executable code for sensing and analyzing fluid characteristics within a conduit of a medical device and air bubbles
ES2864839T3 (en)	2015-07-02	2021-10-14	Turning Point Therapeutics Inc	Chiral diaryl macrocycles as modulators of protein kinases
ES2979111T3 (en)	2015-07-06	2024-09-24	Turning Point Therapeutics Inc	Diaryl macrocycle polymorph
MX383823B (en)	2015-07-21	2025-03-14	Turning Point Therapeutics Inc	CHIRAL DIARYL MACROCYCLES AND THEIR USES.
TN2018000138A1 (en)	2015-10-26	2019-10-04	Array Biopharma Inc	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
WO2017152076A1 (en)	2016-03-04	2017-09-08	Vanderbilt University	Substituted indole mcl-1 inhibitors
CN109715165A (en)	2016-07-28	2019-05-03	Tp生物医药公司	Huge ring kinase inhibitor
JP2020533269A (en)	2016-12-14	2020-11-19	デベロップメントセンターフォーバイオテクノロジー	Antibody-drug conjugates and their use
TWI808958B (en)	2017-01-25	2023-07-21	美商特普醫葯公司	Combination therapy involving diaryl macrocyclic compounds
MY201925A (en)	2017-07-28	2024-03-23	Turning Point Therapeutics Inc	Macrocyclic compounds and uses thereof

2015
- 2015-01-23 WO PCT/US2015/012597 patent/WO2015112806A2/en not_active Ceased
- 2015-01-23 ES ES19169041T patent/ES2933350T3/en active Active
- 2015-01-23 EA EA201892241A patent/EA201892241A1/en unknown
- 2015-01-23 HU HUE19212110A patent/HUE066590T2/en unknown
- 2015-01-23 EP EP19212110.1A patent/EP3636649B1/en active Active
- 2015-01-23 JP JP2016566857A patent/JP6490713B2/en active Active
- 2015-01-23 EA EA201691492A patent/EA031863B1/en active IP Right Revival
- 2015-01-23 HR HRP20221518TT patent/HRP20221518T1/en unknown
- 2015-01-23 HR HRP20191283TT patent/HRP20191283T1/en unknown
- 2015-01-23 EP EP15740510.1A patent/EP3097107B1/en active Active
- 2015-01-23 NZ NZ761094A patent/NZ761094A/en unknown
- 2015-01-23 DK DK19169041.1T patent/DK3572416T3/en active
- 2015-01-23 HR HRP20240503TT patent/HRP20240503T1/en unknown
- 2015-01-23 CA CA2936079A patent/CA2936079C/en active Active
- 2015-01-23 EP EP23220719.1A patent/EP4338739A3/en active Pending
- 2015-01-23 US US15/113,583 patent/US9714258B2/en not_active Ceased
- 2015-01-23 CN CN201580005705.5A patent/CN106170289B/en active Active
- 2015-01-23 RS RS20190900A patent/RS59059B1/en unknown
- 2015-01-23 PE PE2016000959A patent/PE20160931A1/en unknown
- 2015-01-23 ES ES19212110T patent/ES2976459T3/en active Active
- 2015-01-23 CN CN201910549748.XA patent/CN110317214B/en active Active
- 2015-01-23 AU AU2015209239A patent/AU2015209239B2/en active Active
- 2015-01-23 PT PT192121101T patent/PT3636649T/en unknown
- 2015-01-23 HU HUE19169041A patent/HUE060554T2/en unknown
- 2015-01-23 PL PL19212110.1T patent/PL3636649T3/en unknown
- 2015-01-23 LT LTEP19169041.1T patent/LT3572416T/en unknown
- 2015-01-23 SI SI201531908T patent/SI3572416T1/en unknown
- 2015-01-23 SG SG10202000191YA patent/SG10202000191YA/en unknown
- 2015-01-23 US US18/147,888 patent/USRE50634E1/en active Active
- 2015-01-23 HU HUE15740510A patent/HUE045208T2/en unknown
- 2015-01-23 SM SM20240175T patent/SMT202400175T1/en unknown
- 2015-01-23 EP EP19212126.7A patent/EP3636650A1/en not_active Withdrawn
- 2015-01-23 MY MYPI2016001385A patent/MY193524A/en unknown
- 2015-01-23 CN CN201910549014.1A patent/CN110317213B/en active Active
- 2015-01-23 EP EP19212106.9A patent/EP3636648A1/en not_active Withdrawn
- 2015-01-23 RS RS20221161A patent/RS63829B1/en unknown
- 2015-01-23 PT PT191690411T patent/PT3572416T/en unknown
- 2015-01-23 SG SG11201605929RA patent/SG11201605929RA/en unknown
- 2015-01-23 PL PL15740510T patent/PL3097107T3/en unknown
- 2015-01-23 SM SM20230008T patent/SMT202300008T1/en unknown
- 2015-01-23 KR KR1020167020188A patent/KR102402179B1/en active Active
- 2015-01-23 UA UAA201608991A patent/UA121206C2/en unknown
- 2015-01-23 LT LTEP15740510.1T patent/LT3097107T/en unknown
- 2015-01-23 ES ES15740510T patent/ES2735729T3/en active Active
- 2015-01-23 SI SI201530810T patent/SI3097107T1/en unknown
- 2015-01-23 PL PL19169041.1T patent/PL3572416T3/en unknown
- 2015-01-23 EP EP19169041.1A patent/EP3572416B1/en active Active
- 2015-01-23 PT PT15740510T patent/PT3097107T/en unknown
- 2015-01-23 SI SI201531994T patent/SI3636649T1/en unknown
- 2015-01-23 SM SM20190388T patent/SMT201900388T1/en unknown
- 2015-01-23 RS RS20240447A patent/RS65417B1/en unknown
- 2015-01-23 AP AP2016009383A patent/AP2016009383A0/en unknown
- 2015-01-23 NZ NZ722375A patent/NZ722375A/en unknown
- 2015-01-23 MX MX2020001360A patent/MX392904B/en unknown
- 2015-01-23 MX MX2016009588A patent/MX2016009588A/en active IP Right Grant
- 2015-01-23 LT LTEP19212110.1T patent/LT3636649T/en unknown
- 2015-01-23 DK DK15740510.1T patent/DK3097107T3/en active
- 2015-01-23 DK DK19212110.1T patent/DK3636649T3/en active
- 2015-01-23 FI FIEP19212110.1T patent/FI3636649T3/en active
2016
- 2016-07-07 ZA ZA2016/04654A patent/ZA201604654B/en unknown
- 2016-07-20 IL IL246860A patent/IL246860B/en active IP Right Grant
- 2016-07-22 CL CL2016001876A patent/CL2016001876A1/en unknown
- 2016-07-25 PH PH12016501463A patent/PH12016501463B1/en unknown
2017
- 2017-05-31 US US15/609,962 patent/US10246466B2/en active Active
2018
- 2018-11-29 US US16/204,566 patent/US10618912B2/en active Active
2019
- 2019-02-27 JP JP2019034652A patent/JP2019104748A/en not_active Withdrawn
- 2019-07-17 CY CY20191100764T patent/CY1121850T1/en unknown
- 2019-08-21 IL IL268820A patent/IL268820B/en unknown
- 2019-12-10 AU AU2019279951A patent/AU2019279951B2/en active Active
2020
- 2020-02-21 US US16/797,866 patent/US20200216465A1/en not_active Abandoned
- 2020-07-06 ZA ZA2020/04100A patent/ZA202004100B/en unknown
2021
- 2021-01-07 JP JP2021001588A patent/JP2021063121A/en active Pending
- 2021-09-27 US US17/485,942 patent/US20220112213A1/en not_active Abandoned
2022
- 2022-07-08 JP JP2022110613A patent/JP7356546B2/en active Active
2023
- 2023-07-28 US US18/227,561 patent/US12404281B2/en active Active
- 2023-09-22 JP JP2023158350A patent/JP2023179539A/en not_active Ceased
2025
- 2025-03-12 NL NL301322C patent/NL301322I2/en unknown
- 2025-03-13 NO NO2025015C patent/NO2025015I1/en unknown
- 2025-03-20 FI FIC20250015C patent/FIC20250015I1/en unknown
- 2025-03-20 HU HUS2500016C patent/HUS2500016I1/en unknown
- 2025-04-08 LT LTPA2025513C patent/LTPA2025513I1/lt unknown
- 2025-04-09 FR FR25C1013C patent/FR25C1013I1/en active Active

Also Published As

Publication number	Publication date
HUE060554T2 (en)	2023-03-28
CY1121850T1 (en)	2020-07-31
SI3097107T1 (en)	2019-08-30
SMT202300008T1 (en)	2023-03-17
EP3636650A1 (en)	2020-04-15
PH12016501463A1 (en)	2017-02-06
JP2022133462A (en)	2022-09-13
HRP20240503T1 (en)	2024-07-05
US20220112213A1 (en)	2022-04-14
JP7356546B2 (en)	2023-10-04
CL2016001876A1 (en)	2017-02-03
US20170334929A1 (en)	2017-11-23
US12404281B2 (en)	2025-09-02
MX392904B (en)	2025-03-24
IL268820A (en)	2019-10-31
EP4338739A2 (en)	2024-03-20
SG11201605929RA (en)	2016-08-30
PL3572416T3 (en)	2023-02-27
EP3097107A2 (en)	2016-11-30
NL301322I2 (en)	2025-05-27
LT3636649T (en)	2024-04-10
JP2023179539A (en)	2023-12-19
EP3572416B1 (en)	2022-09-21
EP3636649B1 (en)	2024-02-14
JP2017503867A (en)	2017-02-02
EA031863B1 (en)	2019-03-29
NO2025015I1 (en)	2025-03-13
EP3636649A1 (en)	2020-04-15
NZ761094A (en)	2023-02-24
HRP20191283T1 (en)	2019-10-18
ES2976459T3 (en)	2024-08-01
AU2015209239B2 (en)	2019-09-12
PT3636649T (en)	2024-04-09
LT3097107T (en)	2019-07-25
EP4338739A3 (en)	2024-05-29
KR20160111395A (en)	2016-09-26
SG10202000191YA (en)	2020-03-30
USRE50634E1 (en)	2025-10-14
PE20160931A1 (en)	2016-09-21
US10246466B2 (en)	2019-04-02
EP3097107A4 (en)	2017-08-09
HUE045208T2 (en)	2019-12-30
CN110317214A (en)	2019-10-11
US20240140964A1 (en)	2024-05-02
WO2015112806A3 (en)	2015-11-12
EA201691492A1 (en)	2017-06-30
MX2020001360A (en)	2020-03-20
RS59059B1 (en)	2019-08-30
EP3636648A1 (en)	2020-04-15
AP2016009383A0 (en)	2016-08-31
CN110317213A (en)	2019-10-11
FR25C1013I1 (en)	2025-06-20
US20200216465A1 (en)	2020-07-09
CN106170289B (en)	2019-07-23
DK3636649T3 (en)	2024-05-21
HUE066590T2 (en)	2024-08-28
PT3097107T (en)	2019-07-19
MY193524A (en)	2022-10-18
EP3097107B1 (en)	2019-04-17
MX2016009588A (en)	2017-05-15
SI3636649T1 (en)	2024-07-31
IL246860B (en)	2019-09-26
HUS2500016I1 (en)	2025-04-28
PL3636649T3 (en)	2024-05-06
RS63829B1 (en)	2023-01-31
KR102402179B1 (en)	2022-05-25
JP2021063121A (en)	2021-04-22
FIC20250015I1 (en)	2025-03-20
AU2019279951B2 (en)	2021-08-12
ES2933350T3 (en)	2023-02-06
CA2936079C (en)	2022-07-19
US20170002023A1 (en)	2017-01-05
UA121206C2 (en)	2020-04-27
US10618912B2 (en)	2020-04-14
SMT201900388T1 (en)	2019-09-09
DK3097107T3 (en)	2019-07-08
HRP20221518T1 (en)	2023-02-17
ZA201604654B (en)	2020-10-28
EA201892241A1 (en)	2019-02-28
SMT202400175T1 (en)	2024-07-09
LT3572416T (en)	2022-12-27
JP2019104748A (en)	2019-06-27
PH12016501463B1 (en)	2017-02-06
JP6490713B2 (en)	2019-03-27
CN110317213B (en)	2022-10-18
WO2015112806A2 (en)	2015-07-30
EP3572416A1 (en)	2019-11-27
AU2015209239A1 (en)	2016-07-14
CA2936079A1 (en)	2015-07-30
CN106170289A (en)	2016-11-30
PL3097107T3 (en)	2020-01-31
FI3636649T3 (en)	2024-05-02
AU2019279951A1 (en)	2020-01-16
HK1231407A1 (en)	2017-12-22
CN110317214B (en)	2022-11-22
PT3572416T (en)	2022-12-06
IL246860A0 (en)	2016-08-31
LTPA2025513I1 (en)	2025-04-25
ZA202004100B (en)	2023-12-20
IL268820B (en)	2021-10-31
ES2735729T3 (en)	2019-12-20
SI3572416T1 (en)	2023-02-28
NZ722375A (en)	2022-11-25
RS65417B1 (en)	2024-05-31
US9714258B2 (en)	2017-07-25
US20190169207A1 (en)	2019-06-06

Publication	Publication Date	Title
FR25C1013I1 (en)	2025-06-20	DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
DK3394033T3 (en)	2021-01-04	HETEROCYCLIC COMPOUNDS AS IMMUNE MODULATORS
DK3331876T3 (en)	2021-01-11	MODULATORS OF ROR-GAMMA
EP3317285A4 (en)	2019-02-27	CHIRAL DIARYLE MACROCYCLES FOR USE AS MODULATORS OF PROTEIN KINASES
DK3131902T3 (en)	2019-09-02	Compounds like ROR-gamma modulators
DK3137169T3 (en)	2022-02-14	INHIBITORIES OF LYSIN-SPECIFIC DEMETHYLASE-1
DK3294713T5 (en)	2021-05-31	SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS TUBE-GAMMA MODULATORS
DK3628680T3 (en)	2021-10-11	MODULATION OF COMPLEMENTARY ACTIVITY
DK3331863T3 (en)	2020-04-27	HIS UNKNOWN CONNECTIONS AS ROD-GAMMA MODULATORS
DK3348556T3 (en)	2020-08-03	HETEROARYLAMIDES AS INHIBITORS OF PROTEIN AGGREGATION
DK3197868T3 (en)	2020-06-22	N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA [C] PYRROL-NEGATIVE ALLOSTERIC MODULATORS OF NR2B
DK3536324T3 (en)	2021-10-25	4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139
DK3157929T3 (en)	2024-02-05	PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF
DK3389692T3 (en)	2020-03-30	MODULATORS OF COMPLEMENT ACTIVITY
DK3212643T3 (en)	2019-05-13	TRIFLUORMETHYL ALCOHOLS AS ROR-GAMMA-T MODULATORS
DK3212642T3 (en)	2019-11-25	AMID-SUBSTITUTED THIAZOLES AS MODULATORS OF STORAGE MATERIAL
DK3161136T3 (en)	2019-07-01	PROCEDURE FOR REPRESENTATION OF MICROSCOVES